Cognitive Rehabilitation for Cognitive Impairment

Phase-Based Progress Estimates
Cognitive ImpairmentCognitive Rehabilitation - Behavioral
All Sexes
What conditions do you have?

Study Summary

This trial will investigate whether cognitive rehabilitation can help improve cognition for patients with post-COVID-19 cognitive impairment, as well as collect preliminary data on potential connectivity networks underlying the effect of cognitive rehabilitation on cognitive improvements.

Eligible Conditions
  • Cognitive Impairment

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

8 Primary · 8 Secondary · Reporting Duration: end of study, at 12 months

Month 12
Acceptability Scale
Dropout number
Enrollment yield
NACC battery's abbreviated Multilingual Naming Test (MINT)
NACC battery's verbal phonemic and category fluency tests
National Alzheimer's Coordinating Center (NACC) battery's Number Span
Paced Auditory Serial Addition Task (PASAT)
Resting state functional connectivity (rsFC)
Staff Practicality
The Hopkins Verbal Learning Test-Revised (HVLT-R)
The Symbol Digit Modalities Text (SDMT)
Trail Making Test - Part B
Trail Making Test, Part A
Treatment Credibility and Expectancy Questionnaire.
Wide Range Achievement Test, reading subtest, 4th edition (WRAT-4)
Wisconsin Card Sorting Task (WCST)-64

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Brain Health Education Program
1 of 2
Cognitive Rehabilitation
1 of 2

Active Control

Experimental Treatment

60 Total Participants · 2 Treatment Groups

Primary Treatment: Cognitive Rehabilitation · No Placebo Group · N/A

Cognitive Rehabilitation
Experimental Group · 1 Intervention: Cognitive Rehabilitation · Intervention Types: Behavioral
Brain Health Education Program
ActiveComparator Group · 1 Intervention: Brain Health Education Program · Intervention Types: Behavioral
First Studied
Drug Approval Stage
How many patients have taken this drug
Cognitive Rehabilitation

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: end of study, at 12 months

Who is running the clinical trial?

Icahn School of Medicine at Mount SinaiLead Sponsor
779 Previous Clinical Trials
482,951 Total Patients Enrolled
Juan Wisnivesky, MD, DrPhPrincipal InvestigatorIcahn School of Medicine at Mount Sinai

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a confirmed SARS-CoV-2 infection.
You must be able to speak English.
You have objective mild to moderate cognitive impairment, which will be defined as impairment in executive function (a z-score >1.5 standard deviations below the normative mean) and in at least one other cognitive domain.